Bednar E Dimitra, Zon Michael, Abu-Hilal Mohannad
Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada.
Faculty of Engineering, Department of Biomedical Engineering, McMaster University, Hamilton, Ontario, Canada.
Dermatol Surg. 2022 Jan 1;48(1):1-6. doi: 10.1097/DSS.0000000000003250.
Recommendations for the approved use of Mohs surgery for cutaneous melanoma on the trunk and extremities remain uncertain.
To compare survival and recurrence between patients treated with Mohs surgery versus wide excision for melanoma on the trunk and extremities.
The databases Medline, Embase, Web of Science, CENTRAL, and EMCare were searched from inception on January 11, 2021. Contemporary comparisons were included exclusively. Meta-analysis was conducted using generic inverse variance and a fixed effects model.
Four studies were eligible for inclusion. The study population (n = 279,556) was 52.1% men and 97.2% White. There were no observed differences in 5-year overall survival (hazard ratio 0.98, 95% confidence interval 0.90-1.07, I2 = 0%), disease-free survival (HR 0.89, 95% CI 0.12-6.47, I2 = 0), or local recurrence among patients treated with Mohs surgery relative to wide excision. Quality of the evidence was very low.
This systematic review found survival and local recurrence were comparable among patients treated with Mohs surgery or wide excision for melanoma on the trunk and extremities. Future prospective contemporary studies with more diverse representation that report surgical complications and costs may facilitate more definitive recommendations.
对于Mohs手术在躯干和四肢皮肤黑色素瘤的批准使用建议仍不明确。
比较Mohs手术与广泛切除治疗躯干和四肢黑色素瘤患者的生存率和复发率。
检索了Medline、Embase、Web of Science、CENTRAL和EMCare数据库,检索起始时间为2021年1月11日。仅纳入当代比较研究。采用通用逆方差和固定效应模型进行荟萃分析。
四项研究符合纳入标准。研究人群(n = 279,556)中男性占52.1%,白人占97.2%。在5年总生存率(风险比0.98,95%置信区间0.90 - 1.07,I2 = 0%)、无病生存率(HR 0.89,95% CI 0.12 - 6.47,I2 = 0)或Mohs手术治疗患者相对于广泛切除患者的局部复发率方面,未观察到差异。证据质量非常低。
本系统评价发现,Mohs手术或广泛切除治疗躯干和四肢黑色素瘤患者的生存率和局部复发率相当。未来进行更具代表性、报告手术并发症和成本的前瞻性当代研究可能有助于提出更明确的建议。